The biotech and pharmaceutical landscape witnessed significant corporate and regulatory developments. Moderna announced a 10% workforce reduction as part of cost-saving measures in response to falling vaccine demand and tougher FDA approvals. Allogene Therapeutics confirmed a patient death linked to an experimental lymphodepletion drug, prompting trial design changes. Novo Nordisk appointed a new CEO, Maziar Mike Doustdar, marking leadership continuity. Multiple companies including Madrigal, Viridian, and Apellis secured strategic deals expanding global rights and drug approvals. Regulatory shifts continue to impact drug development and commercialization dynamics.